Title: Zinc²⁺ ion inhibits SARS-CoV-2 main protease and viral replication *in vitro*.

Authors: Love Panchariya^{1†}, Wajahat Ali Khan^{1†}, Shobhan Kuila^{1†}, Kirtishila Sonkar¹, Sibasis Sahoo¹, Archita Ghoshal¹, Ankit Kumar², Dileep Kumar Verma², Abdul Hasan², Shubhashis Das³, Jitendra K Thakur³, Rajkumar Halder⁴, Sujatha Sunil², Arulandu Arockiasamy^{1*}

Affiliation:

¹Membrane Protein Biology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067. India.

²Vector Borne Diseases Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067. India.

³Plant Mediator Lab, National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi- 110 067

⁴Ruhvenile Biomedical OPC PVT LTD, Plot No-8, OCF Pocket Institution, Sarita Vihar, New Delhi-110070. India.

[†]These authors contributed equally to the work presented.

For correspondence:

*Correspondence should be addressed to: sam@icgeb.res.in / asamy001@gmail.com

Communicating author:

Arockiasamy Arulandu

International Centre for Genetic Engineering and Biotechnology (ICGEB),

Aruna Asaf Ali Marg,

New Delhi 110067. India.

Phone: +91-11-26741358 Ext-172

Fax: +91-11-26742316

Mobile: +91-9711055502

Abstract:

Zinc deficiency is linked to poor prognosis in COVID-19 patients while clinical trials with Zinc demonstrate better clinical outcome. The molecular target and mechanistic details of anti-coronaviral activity of Zinc remain obscure. We show that ionic Zinc not only inhibits SARS-CoV-2 main protease (Mpro) with nanomolar affinity, but also viral replication. We present the first crystal structure of Mpro-Zn²⁺ complex at 1.9 Å and provide the structural basis of viral replication inhibition. We show that Zn²⁺ coordinates with the catalytic dyad at the enzyme active site along with two previously unknown water molecules in a tetrahedral geometry to form a stable inhibited Mpro-Zn²⁺ complex. Further, natural ionophore quercetin increases the anti-viral potency of Zn²⁺. As the catalytic dyad is highly conserved across SARS-CoV, MERS-CoV and all variants of SARS-CoV-2, Zn²⁺ mediated inhibition of Mpro may have wider implications.

Main Text:

COVID-19 pandemic caused by SARS-CoV-2 is a major clinical challenge^{1 2 3}. Lower serum Zinc concentration at the time of admission of COVID-19 patients correlates with severe clinical presentations; an extended duration to recovery, higher morbidity, and a higher mortality in elderly^{4 5}. However, clinical trials with Zinc and ionophore show positive clinical outcome with a decreased rate of mortality, and transfer to hospice^{6 7 8}

Zinc plays several key roles in biological systems viz. structural, catalytic, regulatory and signalling events^{9 10 11}. Further, Zinc exhibits anti-viral properties¹², including against SARS-CoV. SARS-CoV Main protease (Mpro)¹³ and RNA dependent RNA polymerase (RDRP)¹⁴ are potential key molecular targets of Zinc. However, the structure of SARS-CoV-2 RDRP¹⁵ suggests a structural role for Zinc rather than an inhibitory one. Notably, detailed kinetics and mechanism of ionic Zinc targeting SARS-CoV-2 Mpro is lacking.

We first studied one on one binding kinetics of Zinc acetate with purified SARS-CoV-2 Mpro using Surface Plasmon Resonance (SPR). Zinc binds to SARS-CoV-2 Mpro with an association rate constant (ka) of 8,930±30 M⁻¹s⁻¹ and the dissociation rate constant (kd) of 0.01755±10 s⁻¹, and an equilibrium dissociation constant (KD) of 1.965E-06 M. (**Fig. 1a**) The half-life (t1/2=ln

[0.5]/kd) of Mpro-Zn²⁺ complex is ~40s. We then assessed the inhibitory effects of Zn²⁺ binding on the proteolytic activity of SARS-COV-2 Mpro in the presence of Zinc acetate. We obtained an IC₅₀ value of 325.1 ± 5.1 nM with complete inhibition at 6.25 µM and above (**Fig. 1b**). We also tested Zinc glycinate and Zinc gluconate complexes, which are available as Zinc supplements in the market and are also investigated in COVID-19 clinical trials¹⁶, and obtained IC₅₀ values of 279.35±17.95 nM and 405.25±0.45 nM, respectively (**Supplementary Figure 1a and 1b**). Reversibility of Zn²⁺-mediated inhibition was tested by first inhibiting the enzyme with 500 nM Zinc acetate, and then initiating the reaction with a substrate peptide, followed by addition of EDTA to regain the enzyme activity by chelating Zn²⁺ ions. We find that Zinc inhibition is completely reversible by EDTA (**Supplementary Figure 1c**), suggesting that inhibition by the metal ion is not because of oxidation of catalytic cysteine (Cys145).

To further understand the structural basis of SARS-CoV-2 Mpro inhibition by Zn²⁺ ion, we solved the crystal structure of the bound complex at 1.9 Å (**Supplementary Table 2**). The asymmetric unit contains a dimer of Mpro in space group P2₁2₁2₁ (**Fig. 1c**). An unambiguous electron density for Zn²⁺ (**Fig. 1d, e**) shows that the metal ion is coordinated by the catalytic dyad His41 and Cys145, which is absent in the control datasets collected for apo-enzyme crystals grown in the same condition. Zn²⁺-bound complex shows a tetrahedral coordination geometry at the Mpro active site by coordinating with two water molecules that are absent in the apo-enzyme structure (**Fig. 1c**). Distortion in the tetrahedral geometry observed is attributed to the presence of heterogeneous atoms; sulphur (Cys145-SG) and nitrogen (His41-NE2) in the inhibited complex. A 180° flip of the imidazole ring of His41 brings NE2 closer to Zn²⁺ with an inter-atomic distance of 1.94 Å to form a coordinate bond. The interatomic distance between catalytic Cys145 and Zn²⁺ is 2.36 Å consistent with observed bound complexes. Two structural water molecules W1 and W2 (PDB: 7DK1; HETATM 5028 and 5031, respectively) coordinate Zn²⁺ at an inter-atomic distance of 2.23 Å and 1.98 Å, respectively, to satisfy the tetrahedral geometry (**Fig. 1c**). The coordination of Zn²⁺ with the catalytic dyad is expected to prevent a nucleophilic attack on the carbonyl moiety of the amide bond in polyprotein substrate. We hypothesize that the two strongly coordinated water molecules impart stability to the Zn²⁺ inhibited complex. To gain deeper insights into the stability of Mpro-Zn²⁺ complex, we simulated the complex for 1 µs at 300K, keeping the coordinating waters, W1 and W2. During the simulation, Zn²⁺ remains

strongly bound to the active site via metal coordination bonds with His41 (NE2) and Cys145 (SG) with an interatomic distance of 1.951 ± 0.031 and 2.518 ± 0.031 Å, respectively, throughout the 1 μ s time frame. The mobility of Zn^{2+} ion is restricted with a mean RMSD of 0.920 Å (**Fig. 1f**) in accordance with the dynamics of side chains of coordinating catalytic dyad. Visualization of MD simulation trajectory shows (**Supplementary Movie**) that coordinating water molecules W1 and W2 remain bound to Zn^{2+} throughout the simulation, and help maintain the tetrahedral geometry observed in complex crystal structure (**Fig. 1g**)

We further assessed the inhibitory potential of Zinc acetate, Zinc glycinate and Zinc gluconate against SARS-CoV-2. Infected Vero E6 cells were treated with all the three Zinc salts at their respective maximum non-toxic concentrations (MNTD) for 48 hours. The MNTDs used for the three compounds were 100 μ M for Zinc acetate and Zinc gluconate and 70 μ M for Zinc glycinate. We observed that Zinc acetate treatment resulted in more than 50% reduction of viral titre, as compared to the untreated infected cells (**Fig. 2a**). Based on these results, we determined the IC_{50} of Zinc acetate to be 3.227 μ M (**Fig 2b**). Surprisingly, Zinc glycinate and Zinc gluconate failed to inhibit viral replication in standard antiviral assays at non-toxic concentrations albeit showing effective enzyme inhibition *in vitro*. Quercetin, a natural Zinc ionophore, increases the bioavailability of Zinc in treated cells¹⁷, which prompted us to ask whether an increased bioavailability of Zn^{2+} results in enhanced inhibition of viral replication. To test this, we mixed Zinc acetate with Quercetin at 1:2 molar ratio¹⁸ at non-toxic concentrations (**Supplementary Figure 2**) and tested the antiviral activity against SARS-CoV-2. We observed >2-fold viral inhibition in the presence of Quercetin (**Fig. 2c**).

Taken together, our data strongly suggest an inhibitory role for ionic Zinc¹¹, wherein it inhibits SARS-CoV-2 Mpro enzyme activity, supported by complex crystal structure and subsequent inhibition of viral replication *in vitro*. Known crystal structures of Zinc conjugates such as N-ethyl-n-phenyl-dithiocarbamic acid (EPDTC), JMF1600, and Zinc-pyrithione in complex with 3C-like (Mpro) proteases from coronavirus¹⁹, including SARS-CoV²⁰ and SARS-CoV-2²¹, show a similar mode of metal ion coordination with the catalytic dyad (**Supplementary Figure 3**). However, the Zn^{2+} inhibited SARS-CoV-2 Mpro enzyme structure presented in this study clearly suggests that ionic form of Zinc alone is capable of inhibiting the enzyme, by forming a stable complex at the active site with the help of two water molecules, previously unknown. We further

show Zinc complexes; Zinc glycinate and Zinc gluconate failed to show any antiviral effects in our cell culture experiments. Most notably, we show that Zinc ionophore Quercetin aids in inhibition of SARS-CoV-2 replication as it increases the intracellular concentration of Zinc¹⁷. Our data support the findings that a combination of Zinc salt, which provides ionic Zinc, with ionophores^{6 7 8}, may have a better clinical outcome in COVID-19 therapy. As the Zn²⁺ coordinating catalytic dyad; Cysteine and Histidine is conserved across all coronaviral 3C-like proteases (Mpro), including the variants of SARS-CoV-2, the mode of Zn²⁺ mediated inhibition is expected to be similar. Whether Zn²⁺ targets Mpro *in vivo* requires further investigation.

Data accessibility: Mpro-Zinc²⁺ complex coordinates are available at PDB: 7DK1. X-ray raw data is available from Integrated Resource for Reproducibility in Macromolecular Crystallography (IRRCMC) repository (<https://proteindiffraction.org/>).

Acknowledgement: We thank Prof. Rolf Hilgenfeld, Institute of Biochemistry, University of Lübeck, Lübeck, Germany for providing the expression construct for SARS-CoV-2 Mpro. We thank the beamline staff at the Elettra XRD2 particularly Raghurama P. Hegde and Annie Heroux for beamline support. Access to the XRD2 beamline at the Elettra synchrotron, Trieste was made possible through grant-in-aid from the Department of Science and Technology, India, vide grant number DSTO-1668. The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. We thank Prof. Ramesh Sonti, former Director, NIPGR, New Delhi for access to Biacore T-200. This work was supported by ICGB core grant and Govt. of India DST-SERB IRHPA grant: IPA/2020/000285.

Author contribution: LP, WK, SK, KS purified Mpro and performed biochemical and SPR experiments and SD and JKT helped with SPR experiments and data analysis. LP and KS crystallized, collected X-ray data and solved the structure. LP and SS performed MD simulation and analysis. AG performed cytotoxicity assays. AK, DV, AH and S. Sunil performed anti-viral assays and analysed the data. RH provided inputs to biochemical assays. AA coordinated the work and LP and AA wrote the manuscript with inputs from all the authors.

Conflict of interest: The authors declare no conflict of interest.

Figure 1. Zn²⁺ binds at the active site and inhibits SARS-CoV-2 Mpro enzyme activity: (a) Interaction kinetics of Zn²⁺ with immobilized Mpro using surface plasmon resonance (SPR) shows affinity (KD) of 1.96 µM. Coloured lines indicate various concentrations of Zinc acetate.

146 **(b)** IC₅₀ and concentration dependent inhibition of Mpro by Zn²⁺ ion. **(c)** Complex crystals
 147 structure of Mpro dimer with Zinc (grey sphere) bound at the active site of both protomers. On
 148 the right, catalytic dyad Cys145 and His41 of Mpro is shown with bound Zinc in tetrahedral
 149 coordination geometry. **(d)** Electron density map (2Fo-Fc) contoured at 1 σ showing the catalytic
 150 dyad in Apo-Mpro **(e)** Omit difference map (Fo-Fc contoured at 3 σ) shows unambiguous
 151 density (green) for Zn²⁺ (grey) and two metal-ion coordinating structural water molecules (red).
 152 **(f)** 1 μ s MD simulation Mpro-Zn²⁺ complex shows low RMSD of Zn²⁺ (blue) and protein
 153 backbone (red) indicating stability of inhibited state **(Supplementary video)** **(g)** Distance plot
 154 shows less fluctuations in inter-atomic distances between Zn²⁺ and two coordinating water
 155 molecules during the course of simulation, representing stable metal ion-water interactions in the
 156 inhibitory role of Zn²⁺.

Figure 2. Anti-SARS-CoV-2 activity of Zinc and its complexes with ionophore in infected Vero E6 cells. **(a)** Zinc acetate inhibits SARS-CoV-2 replication in Vero E6 cells as determined using qRT-PCR. Treatment with Zinc acetate (100 μM) for 48 h resulted in >50% reduction of viral titre while the Zinc glycinate and Zinc gluconate complexes did not show significant reduction. **(b)** IC₅₀ determination using varying concentrations of Zinc acetate for 48 h followed by viral quantification using plaque assay. **(c)** Viral inhibition by Zinc acetate and Quercetin mixture (1:2 M ratio). Mean percentage reduction of SARS-CoV-2 is indicated within the bars. The antiviral experiments were repeated at least twice, and each experiment included at least three replicates. Statistical significance was determined using Student's t-test (n ≥ 2 biological replicates).

References

- 1 Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265-269, doi:10.1038/s41586-020-2008-3 (2020).
- 2 Wise, J. Covid-19: New coronavirus variant is identified in UK. *BMJ* **371**, m4857, doi:10.1136/bmj.m4857 (2020).
- 3 Yadav, P. D. *et al.* Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage. *J Travel Med* **28**, doi:taab009 [pii] (2021).
- 4 Jothimani, D. *et al.* COVID-19: Poor outcomes in patients with zinc deficiency. *Int J Infect Dis* **100**, 343-349, doi:S1201-9712(20)30730-X [pii] (2020).
- 5 Vogel-Gonzalez, M. *et al.* Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. *Nutrients* **13**, doi:562 [pii] (2021).
- 6 Carlucci, P. M. *et al.* Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. *J Med Microbiol* **69**, 1228-1234, doi:10.1099/jmm.0.001250 (2020).
- 7 Frontera, J. A. *et al.* Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. *Res Sq*, doi:rs.3.rs-94509 [pii] (2020).
- 8 Derwand, R., Scholz, M. & Zelenko, V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *Int J Antimicrob Agents* **56**, 106214, doi:S0924-8579(20)30425-8 [pii] (2020).
- 9 Kochanczyk, T., Drozd, A. & Krezel, A. Relationship between the architecture of zinc coordination and zinc binding affinity in proteins--insights into zinc regulation. *Metallomics* **7**, 244-257, doi:10.1039/c4mt00094c (2015).
- 10 Maret, W. Inhibitory zinc sites in enzymes. *Biometals* **26**, 197-204, doi:10.1007/s10534-013-9613-7 (2013).
- 11 Maret, W. Zinc coordination environments in proteins determine zinc functions. *J Trace Elem Med Biol* **19**, 7-12, doi:S0946-672X(05)00012-X [pii] (2005).
- 12 Read, S. A., Obeid, S., Ahlenstiel, C. & Ahlenstiel, G. The Role of Zinc in Antiviral Immunity. *Adv Nutr* **10**, 696-710, doi:10.1093/advances/nmz013 (2019).
- 13 Hsu, J. T. *et al.* Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. *FEBS Lett* **574**, 116-120, doi:10.1016/j.febslet.2004.08.015

209 S0014579304010087 [pii] (2004).
210 14 te Velthuis, A. J. *et al.* Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro
211 and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* **6**,
212 e1001176, doi:10.1371/journal.ppat.1001176 (2010).
213 15 Kokic, G. *et al.* Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. *Nat Commun* **12**,
214 279, doi:10.1038/s41467-020-20542-0
215 10.1038/s41467-020-20542-0 [pii] (2021).
216 16 Thomas, S. *et al.* Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on
217 Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The
218 COVID A to Z Randomized Clinical Trial. *JAMA Network Open* **4**, e210369-e210369,
219 doi:10.1001/jamanetworkopen.2021.0369 (2021).
220 17 Dabbagh-Bazarbachi, H. *et al.* Zinc ionophore activity of quercetin and epigallocatechin-gallate:
221 from Hepa 1-6 cells to a liposome model. *J Agric Food Chem* **62**, 8085-8093,
222 doi:10.1021/jf5014633 (2014).
223 18 Bratu, M. *et al.* Biological Activities of Zn(II) and Cu(II) Complexes with Quercetin and Rutin:
224 Antioxidant Properties and UV-Protection Capacity. *Revista de Chimie* **65**, 544-549 (2014).
225 19 Lee, C. C. *et al.* Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-
226 coordinating and peptidomimetic compounds. *J Biol Chem* **284**, 7646-7655,
227 doi:10.1074/jbc.M807947200
228 S0021-9258(20)32476-5 [pii] (2009).
229 20 Lee, C. C. *et al.* Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like
230 protease inhibitors. *FEBS Lett* **581**, 5454-5458, doi:S0014-5793(07)01116-7 [pii]
231 10.1016/j.febslet.2007.10.048 (2007).
232 21 Gunther, S. *et al.* X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2
233 main protease. *Science* **372**, 642-646, doi:10.1126/science.abf7945
234 science.abf7945 [pii] (2021).
235
236